ATM and prostate carcinoma: On the other hand, the first major biomarker study in prostate cancer (PCa) (the PROfound study) reported that 17.6% of the 4425 patients had mutations in at least one of the predefined 15 HRR genes, which included BRCA1, BRCA2, and ATM [42].